CVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004

Size: px
Start display at page:

Download "CVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004"

Transcription

1 Changes in JNC VII Blood Pressure Categories Blood Pressure Category Initial Value ¹ Latest Value ¹ Improvement ² (Based on JNC VII Guidelines) values (days) (N=271) (N = 209) Normal (SBP < 120 and DBP < 80) 62 ( 23%) 106 ( 39%) (49%) Prehypertension (SBP or DBP 0-89) 129 ( 48%) 117 ( 43%) Stage 1 (SBP or DBP 90-99) 65 ( 24%) 40 ( 15%) Stage 2 (SBP >/= 160 or DBP >/= 100) 15 ( 6%) 8 ( 3%) ¹Blood pressure values included in this table are from all data sources. ²Improvement is defined as patients with an initial value in the Prehypertension, Stage 1, or Stage 2 category who improved at least one category with their latest value. (i.e. moved from Stage 2 to Stage 1). Changes in LDL Cholesterol Levels LDL Category Initial Value ¹ Latest Value ¹ Improvement ² (Based on ATP III Guidelines) values (days) (N=36) Less than ( 50%) 24 ( 67%) ( 28%) 6 ( 17%) ( 11%) 4 ( 11%) ( 8%) 2 ( 6%) Greater than or equal to ( 3%) 0 ( 0%) (N=21) ³ (N=11) At LDL Goal¹¹ 10 ( 48%) 14 ( 67%) 4 (36%) Not at LDL Goal¹¹ 11 ( 52%) 7 ( 33%) ¹LDL Values included in this table are from all data sources. ²Improvement is defined as those patients who were not at goal with the initial value but met their goal with the latest value. ³Patients included are those with at least two LDL values recorded during the reporting period who also had an LDL goal in place at the time each LDL value was collected. Page 1 of 6

2 ¹¹LDL Goals are set by the Care Manager based on the ATP III guidelines or Care Manger discretion. Changes in ACC/AHA Heart Failure Treatment Classes ACC/AHA Heart Failure Treatment Class (N=356) Initial Value Latest Value Stage A 0 ( 0%) 0 ( 0%) Stage B 15 ( 4%) 10 ( 3%) Stage C 341 ( 96%) 346 ( 97%) Stage D 0 ( 0%) 0 ( 0%) Diastolic dysfunction 0 ( 0%) 0 ( 0%) Changes in New York Heart Association (NYHA) Classes Among Patients with Heart Failure Heart Failure patients with NYHA classifications (N=287) Initial Value Latest Value values (days) Improvement ¹ (N=167) Class I 120 ( 42%) 149 ( 52%) (62 %) Class II 87 ( 30%) 98 ( 34%) Class III 43 ( 15%) 27 ( 9%) Class IV 37 ( 13%) 13 ( 5%) ¹Improvement is defined as those patients who were initially in Class II, III, or IV and improved at least one class with the latest value (i.e. moved from Class II to Class I). Changes in Daily Weight Monitoring Among Patients with Heart Failure Heart Failure Patients with Questionnaire Initial Value Latest Value Improvement ¹ Responses to Weight Monitoring values (days) (N=3) (N=1) Daily² 2 ( 67%) 2 ( 67%) (0 %) Page 2 of 6

3 Changes in Daily Weight Monitoring Among Patients with Heart Failure (Continued) Heart Failure Patients with Questionnaire Initial Value Latest Value Improvement ¹ Responses to Weight Monitoring values (days) ¹Improvement is defined as those patients who were not monitoring weight daily at the initial value and were monitoring weight daily with the latest value. ²Daily weight monitoring is determined by the patients's response of "Daily" to a specific question within a CVD questionnaire that asks "How often do you currently weigh yourself to monitor your heart failure signs and symptoms at home?" Medication Use Among Patients in Symptomatic ACC/AHA Heart Failure Treatment Classes Medication Type Continuous Use¹ Delayed start, then Used, then discontinued³ Intermittent Use¹¹ No Use²¹ continuous use² ACC/AHA Class: Stage C & D (N=346) ¹² ACE inhibitors 223 ( 64%) 7 ( 2%) 24 (7 %) 0 (0%) 82 (24 %) ARBs¹³ 19 ( 5%) 9 ( 3%) 3 (1 %) 0 (0%) 113 (33 %) Beta-blockers 191 ( 55%) 9 ( 3%) 12 (3 %) 4 (1%) 121 (35 %) Diuretics 293 ( 85%) 6 ( 2%) 5 (1 %) 2 (1%) 36 (10 %) Digoxin 95 ( 27%) 2 ( 1%) 7 (2 %) 0 (0%) 235 (68 %) ACC/AHA Class: Diastolic Dysfunction (N=0) Diuretics 0 ( 0%) 0 ( 0%) 0 (0 %) 0 (0%) 0 (0 %) ¹Includes patients who were on the medication for the entire report period -or- were given the ACC/AHA classification during the report period and started the medication within 30 days of the classification and continued taking it until the end of the report period. ²Includes patients who were given the ACC/AHA classification prior/during the report period and started the medication more than 30 days after the classification occurred and continued taking it until the end of the report period. ³Includes patients who were on the medication at some time during the report period but discontinued use for the remainder of the report period. ¹¹Includes patients who were on the medication two or more times during the report period but had discontinued use in between the times it was being taken. ¹²The sum of the percentages for patients within a column may exceed 100% because the patients could have been on multiple medications. Page 3 of 6

4 ¹³The values for ARBs have the potential for being understated as the data is only collected within the Clinical Data module and is not currently collected via questionnaires like the other medications in this section. ²¹Includes patients that had only a "No" value entered for the medication category for the report period. Changes in Canadian Cardiovascular Society (CCS) Angina Classes CCS Class Initial Value Latest Value values (days) Improvement ¹ (N=1) ² (N=1) No Angina ( 100%) (100 %) Class I 0 ( 0%) 0 ( 0%) Class II 0 ( 0%) 0 ( 0%) Class III 1 ( 100%) 0 ( 0%) Class IV 0 ( 0%) 0 ( 0%) ¹Improvement is defined as those patients who were initially in Class I, II, III or IV and improved at least one class or moved to No Angina with the latest value (i.e. moved from Class IV to Class III or moved from Class I to No Angina). ²Patients with No Angina for the latest value will be included in this table if the initial value was Class I, Class II, Class III, or Class IV. Medication Use Among Patients with a Prior Myocardial Infarction Medication Type Continuous Use¹ Delayed start, then Used, then discontinued³ Intermittent Use¹¹ No Use²¹ continuous use² Patients with prior MI (N=199) ¹² ACE inhibitors 83 ( 42%) 51 ( 26%) 14 (7 %) 0 (0 %) 46 (23 %) ARBs¹³ 9 ( 5%) 9 ( 5%) 1 (1 %) 0 (0 %) 62 (31 %) Beta-blockers 77 ( 39%) 54 ( 27%) 8 (4 %) 2 (1 %) 55 (28 %) Antiplatelet/Anticoagulation (includes Aspirin, Clopidogrel, and Warfarin) 95 ( 48%) 65 ( 33%) 0 (0 %) 1 (1 %) 9 (5 %) Page 4 of 6

5 ¹Includes patients who were on the medication for the entire report period -or- had an MI reported during the report period and started the medication within 30 days of the reported MI and continued taking it until the end of the report period. ²Includes patients who had an MI reported prior/during the report period and started the medication more than 30 days after the MI was reported and continued taking it until the end of the report period. ³Includes patients who were on the medication at some time during the report period but discontinued use for the remainder of the report period. ¹¹Includes patients who were on the medication two or more times during the report period but had discontinued use in between the times it was being taken. ¹²The sum of the percentages for patients within a column may exceed 100% because the patients could have been on multiple medications. ¹³The values for ARBs have the potential for being understated as the data is only collected within the Clinical Data module and is not currently collected via questionnaires like the other medications in this section. ²¹Includes patients that had only a "No" value entered for the medication category for the report period. AntiPlatelet/AntiCoagulant Use Among Patients with Atrial Fibrillation Medication Type Continuous Use¹ Delayed start, then Used, then discontinued³ Intermittent Use¹¹ continuous use² Patients with Atrial Fibrillation (N=162) ¹² Aspirin 83 ( 51%) 7 ( 4%) 6 (4 %) 1 (1 %) Clopidogrel 13 ( 8%) 0 ( 0%) 1 (1 %) 0 (0 %) Warfarin 66 ( 41%) 8 ( 5%) 4 (2 %) 0 (0 %) No use of aspirin, clopidogrel, or warfarin: 10 ( 6%) ¹Includes patients who were on the medication for the entire report period -or- had a diagnosis of atrial fibrillation during the report period and started the medication within 30 days of the diagnosis and continued taking it until the end of the report period. ²Includes patients who had a diagnosis of atrial fibrillation prior/during the report period and started the medication more than 30 days after the diagnosis was reported and continued taking it until the end of the report period. ³Includes patients who were on the medication at some time during the report period but discontinued use for the remainder of the report period. ¹¹Includes patients who were on the medication two or more times during the report period but had discontinued use in between the times it was being taken. ¹²The sum of percentages for patients within a column may exceed 100% because the patients could have been on multiple medications. Page 5 of 6

6 Changes in INR Goal Achievement INR /Goal Initial Value Latest Value Relationship values (days) (N=21) ¹ INR within goal range 7 ( 33%) 8 ( 38%) 311 INR above goal range 12 ( 57%) 12 ( 57%) INR below goal range 2 ( 10%) 1 ( 5%) ¹Patients included are those with at least two INR values recorded during the reporting period who also had a goal in place at the time each INR value was collected. Changes in Mean SF-12 Scores Among Patients in the CVD Program and Patients with Heart Failure SF-12 Questionnaire Component Initial Value Latest Value Mean Score (SD) Mean Score (SD) values (days) Patients in CVD Program (N=249) Mental Health Score 54.4 (8.11 ) 55.1 (7.70 ) 353 Physical Health Score 36.9 (10.83 ) 36.8 (10.73 ) Patients with Heart Failure (N=197) Mental Health Score 54.9 (7.67 ) 55.7 (7.23 ) 398 Physical Health Score 37.7 (10.94 ) 37.4 (10.79 ) Page 6 of 6

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa

Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa Right Ventricular Systolic Dysfunction is common in Hypertensive Heart Failure: A Prospective Study in Sub-Saharan Africa 1 Ojji Dike B, Lecour Sandrine, Atherton John J, Blauwet Lori A, Alfa Jacob, Sliwa

More information

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Coronary Heart Disease

Coronary Heart Disease Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has

More information

Online Appendix (JACC )

Online Appendix (JACC ) Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

Key Issues in Cardiovascular Medicine Lindsay Saleski, DO

Key Issues in Cardiovascular Medicine Lindsay Saleski, DO Key Issues in Cardiovascular Medicine Lindsay Saleski, DO Key Issues in Cardiovascular Health L i n d s a y S a l e s k i D O, M B A F a m i l y M e d i c i n e / E m e r g e n c y M e d i c i n e M i

More information

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,

More information

Incorporating KT Concepts within Clinical Trials

Incorporating KT Concepts within Clinical Trials Incorporating KT Concepts within Clinical Trials The RELY-ABLE Trial as an Example Stuart Connolly & Robby Nieuwlaat Background - Dabigatran RE-LY Atrial fibrillation (AF) patients at high risk for stroke

More information

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation

More information

ADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES

ADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES ADULT CARDIOVASCULAR CLINICAL PRACTICE GUIDELINES Risk Intervention Lifestyle Interventions Hypertension Cholesterol Management Recommendations 1. Smoking cessation 2. Maintain ideal weight or weight reduction

More information

2018 HPN Provider Summary Guide. Adult Cardiology Patients (18 Years and Older) Referral Guidelines

2018 HPN Provider Summary Guide. Adult Cardiology Patients (18 Years and Older) Referral Guidelines 12.2 CARDIOLOGY REFERRAL GUIDELINES Contracted Group: Southwest Medical Associates For Appointments: 888 S. Rancho Las Vegas, NV 89109 Phone: (702) 877-8654 Fax: (702) 242-7998 Adult Cardiology Patients

More information

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

Condition/Procedure Measure Compliance Criteria Reference Attribution Method Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is

More information

AUGUST 25-27, 2017 UPDATE & BOARD REVIEW. acofp INTENSIVE. Matters of the Heart. Marissa Rogers, DO INNOVATIVE COMPREHENSIVE HANDS-ON

AUGUST 25-27, 2017 UPDATE & BOARD REVIEW. acofp INTENSIVE. Matters of the Heart. Marissa Rogers, DO INNOVATIVE COMPREHENSIVE HANDS-ON acofp INTENSIVE UPDATE & BOARD REVIEW AUGUST 25-27, 2017 Loews Chicago O'Hare Hotel Rosemont, IL INNOVATIVE COMPREHENSIVE HANDS-ON Matters of the Heart Marissa Rogers, DO acofp Am eric an College of Osteopathi

More information

Heart failure hospitalizations with preserved or reduced ejection fraction

Heart failure hospitalizations with preserved or reduced ejection fraction Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,

More information

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Cardiovascular risk reduction in diabetes Lipids (NICE CG181) Primary Prevention T1DM Offer Atorvastatin 20mg if >40 years old Diabetes duration >10 years Established nephropathy Other CVS risk factors

More information

Hypertension Guidelines 2017

Hypertension Guidelines 2017 Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,

More information

DEPARTMENT OF GENERAL MEDICINE WELCOMES

DEPARTMENT OF GENERAL MEDICINE WELCOMES DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global

More information

Best Practices in Cardiac Care: Getting with the Guidelines

Best Practices in Cardiac Care: Getting with the Guidelines Best Practices in Cardiac Care: Getting with the Guidelines December 9, 2014 Agenda Cardiovascular Disease: How do the guidelines fit into an implementation scheme? What the guidelines set out to accomplish

More information

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding

More information

What s In the New Hypertension Guidelines?

What s In the New Hypertension Guidelines? American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine

More information

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

Management of Hypertension. Ahmed El Hawary MD Suez Canal University Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

Update on Current Trends in Hypertension Management

Update on Current Trends in Hypertension Management Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

Conflict of interest statement

Conflict of interest statement Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

How Low Do We Go? Update on Hypertension

How Low Do We Go? Update on Hypertension How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states

More information

Aha blood pressure guidelines 2016 chart. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

Aha blood pressure guidelines 2016 chart. Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu Search for: Search Search Aha blood pressure guidelines 2016 chart Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu 10-2-2012 Here we explain what blood pressure is, how it is measured, and

More information

Combination Therapy for Hypertension

Combination Therapy for Hypertension Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP

More information

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. 1 Phar6122: CV section Date: 3/21/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Patient: was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Discharge Diagnoses include: q CAD-CCS Class: m 0 m 1 m 2 m 3 m 4 q Unstable angina q Non STEMI (non-st

More information

Improving Quality of Care for Medicare Patients: Accountable Care Organizations

Improving Quality of Care for Medicare Patients: Accountable Care Organizations DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE

More information

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,

More information

Disclosure Information : No conflict of interest

Disclosure Information : No conflict of interest Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

An EMR Specifically Designed for the Cardiovascular Practice

An EMR Specifically Designed for the Cardiovascular Practice An EMR Specifically Designed for the Cardiovascular Practice Gary Chaisson RTR, RCSA Co-Founder Objective Medical Systems May 30, 2017 Disclosure Major Shareholder Objective Medical Systems EMR History

More information

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?

More information

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator

More information

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card

More information

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to: 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital

Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC

More information

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose. JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I

More information

Group Practice Reporting Option I (GPRO I)

Group Practice Reporting Option I (GPRO I) 2011 Physician Quality Reporting System (Physician Quality Reporting) Previously known as Physician Quality Reporting Initiative (PQRI) Group Practice Reporting Option I (GPRO I) Narrative Measure Specifications

More information

WPCCS May2013. Mr Ian Williams Consultant Vascular Surgeon UHW. Consultant Cardiologist UHW

WPCCS May2013. Mr Ian Williams Consultant Vascular Surgeon UHW. Consultant Cardiologist UHW Peripheral Vascular Disease WPCCS May2013 Mr Ian Williams Consultant Vascular Surgeon UHW Prof Julian Halcox Prof Julian Halcox Consultant Cardiologist UHW Case 1? Ischaemic Legs History 85 years lady?varicose

More information

Cardiovascular Pharmacotherapy Update

Cardiovascular Pharmacotherapy Update Cardiovascular Pharmacotherapy Update Debby Caraballo, PharmD, PhC, BCPS April 30 th 2011 Objectives Review recent updates in cardiovascular pharmacotherapy Discuss the updates to Afib, UA/NSTEMI, STEMI/PCI

More information

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Anticoagulants and Head Injuries Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar Common Anticoagulants and Indications Coumadin (warfarin) indicated for

More information

Blood Pressure LIMBO How Low To Go?

Blood Pressure LIMBO How Low To Go? Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity

More information

Blood Pressure Acre Surgery Diviash Thakrar

Blood Pressure Acre Surgery Diviash Thakrar Blood Pressure Acre Surgery Diviash Thakrar Why Are We Doing This? 1. Improve education for patients within the practice 2. Allow us use this for general health promotion Raise money for charity 3. Raise

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Hypertension JNC 8 (2014)

Hypertension JNC 8 (2014) Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology

More information

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM Faculty Disclosure I have no financial interest to disclose No off-label use of medications will be discussed FIFTH ANNUAL SYMPOSIUM Recognize changes between

More information

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of

More information

Intravenous Inotropic Support an Overview

Intravenous Inotropic Support an Overview Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)

More information

Secondary Prevention of Coronary Heart Disease

Secondary Prevention of Coronary Heart Disease Secondary Prevention of Coronary Heart Disease Samornrat Jampates, MD. Cardiology department, CCIT 6 March 2014 Circulation. 2011;123:2274-2283. A B C D E S ABCDE + S Approach to Secondary CAD Prevention

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction Masahito Shigekiyo, Kenji Harada, Ayumi Okada, Naho Terada, Hiroyoshi Yoshikawa, Akira Hirono,

More information

The University of Mississippi School of Pharmacy

The University of Mississippi School of Pharmacy LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.

More information

Pharmaceutical Care of People with Atrial Fibrillation. Course activities

Pharmaceutical Care of People with Atrial Fibrillation. Course activities Pharmaceutical Care of People with Atrial Fibrillation Course activities Pharmaceutical Care of People with Atrial Fibrillation Course activities page 3 Case Study 1 5 Case Study 2 7 Case Study 3 9 Case

More information

Intervention Recommendations with Class of Recommendation and Level of Evidence

Intervention Recommendations with Class of Recommendation and Level of Evidence Intervention Recommendations with Class of Recommendation and Level of Evidence RISK: BLOOD PRESSURE CONTROL: LIPID Goal: to identify people who will benefit from risk reduction strategies Goal:

More information

Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice

Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective

More information

hypertension Head of prevention and control of CVD disease office Ministry of heath

hypertension Head of prevention and control of CVD disease office Ministry of heath hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension

More information

Heart disease in Women

Heart disease in Women Heart disease in Women Extent and risk assessment Charles McCreery MB FACC St Vincent's Hospital Dublin St Columcille s Hospital Dublin Natural Progression of Atherosclerosis Heart disease risk differs

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart

More information

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older)

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older) 2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures)

More information

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp

Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in hs-crp Página 1 de 5 Return to Medscape coverage of: American Society of Hypertension 21st Annual Scientific Meeting and Exposition Val-MARC: Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions

More information

Controversies in Hypertension and Are We Winning the Battle with Heart Disease? Stephen Battista MD

Controversies in Hypertension and Are We Winning the Battle with Heart Disease? Stephen Battista MD Controversies in Hypertension and Are We Winning the Battle with Heart Disease? Stephen Battista MD No Disclosures Deaths per 100,000 UNITED STATES DEATHS RATES 1900-1950 400 Heart Disease Cancer 350 Tuberculosis

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Hayes J, Jackson JL, McNutt GM, Hertz BJ, Ryan JJ, Pawlikowski SA. Association between physician time-unlimited vs time-limited internal medicine board certification and ambulatory

More information

An Epidemiological Overview

An Epidemiological Overview An Epidemiological Overview Cardiovascular disease (CVD) is the leading cause of death in the U.S. In 2005 CVD accounted for approximately 38 percent of all deaths CVD has been the number one killer in

More information

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang, Chung-Shiuan Chen, Qi Zhao, Jing Chen for CATIS

More information

Metoprolol Succinate SelokenZOC

Metoprolol Succinate SelokenZOC Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic

More information

The ESC Registry on Chronic Ischemic Coronary Disease

The ESC Registry on Chronic Ischemic Coronary Disease EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University

More information

Using the New Hypertension Guidelines

Using the New Hypertension Guidelines Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in

More information

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study Dr. Antonio Magaña M.D. (on behalf I-PREFER investigators group) Stockholm, Sweden, August

More information

was admitted to the Cardiology Service

was admitted to the Cardiology Service Patient: was admitted to the Cardiology Service at the to Y from Y /M /D /M /D under the care of Dr.. Discharge Diagnoses include: q CAD-CCS Class: m 0 m 1 m 2 m 3 m 4 q Unstable angina q Non STEMI (non-st

More information

Medical Apps for Cardiology Uses. There s an App for That!

Medical Apps for Cardiology Uses. There s an App for That! Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated

More information

Population models of health impact of combination polypharmacy

Population models of health impact of combination polypharmacy Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067

More information

Course Schedule: Pharmacotherapy II Spring 2011 Revised 12/6/2010

Course Schedule: Pharmacotherapy II Spring 2011 Revised 12/6/2010 Course Schedule: Pharmacotherapy II Spring 2011 Revised 12/6/2010 All lectures will be held from 9:05-11:00 am Monday and Wednesday, as well as 10:10-11:00 am Friday in room MoosT 1-450 and LS 163 (),

More information

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials Marc A. Pfeffer, MD, PhD; Brian Claggett, PhD; Susan F. Assmann,

More information